Martin Edwards

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Burlington, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Andrew Fisher, Attorney-in-fact for Martin Edwards
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Martin Edwards

Form 4 holding Director

Morphic Holding, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
$0
Report date
16 Aug 2024
Price
$55.79
Ownership
Direct
Form 4 holding Director

Verona Pharma plc

Security class
Restricted Share Units
Shares / value
96,000
Estimated value
Report date
25 Apr 2025
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

Verona Pharma plc

Security class
Restricted Stock Units
Shares / value
72,000
Estimated value
Report date
01 Aug 2025
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

Inozyme Pharma, Inc.

Security class
Stock Option (right to buy)
Shares / value
28,000
Estimated value
Report date
18 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

KalVista Pharmaceuticals, Inc.

Security class
Director Stock Option (Right to Buy)
Shares / value
10,000
Estimated value
Report date
30 Sep 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Morphic Holding, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
16 Aug 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

REATA PHARMACEUTICALS INC

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
26 Sep 2023
Price
Ownership
Direct
Underlying class
Class A common stock
Underlying amount
Form 4 holding Director

Verona Pharma plc

Security class
Share Options (Right to Buy)
Shares / value
0
Estimated value
Report date
07 Oct 2025
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount

Insider Reports Filed by Martin Edwards

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .